News & Press

SNIPR_BIOME_Lab.jpg
 
 
SNIPR_IDA_Christian_Groendahl_Interview_CRISPR.jpg

Future Talks / 03.06

IDA Future Talks with Christian Grøndahl

 
SNIPR_Biome_Press_Release_Patents_01.jpg

Press Release / 01.20

SNIPR BIOME Strengthens Lead in CRISPR-based Medicines to Treat Microbiomes

 
SNIPR_BIOME_CRISPR_Nome.jpg

Nome Magazine / 12.19

Back to the basics: CRISPR in bacteria can become the next big pharmaceutical breakthrough

 
SNIPR_BIOME_CRISPR_BusinessInsights.jpg

Business Insights / 12.19

CRISPR Technology: Assassinating Superbugs and Creating a New Paradigm

 
SNIPR_EY_Entrepreneur_of_the_Year_Video.jpg

EY / 11.19

EY Entrepreneur Of The Year 2019 / Life Sciences – video presentation of
SNIPR BIOME [in Danish]

 
SNIPR_EY_Entrepreneur_of_the_Year_Video_02.jpg

EY / 11.19

EY Entrepreneur Of The Year 2019 / Life Sciences – video of award show [in Danish / English]

 
SNIPR_EY_Entrepreneur_of_the_year.jpg

EY / 11.19

SNIPR BIOME wins the prestigious "EY Entrepreneur Of The Year 2019 / Life Sciences" award

 
SNIPR_BIOME_News_CRISPR.jpg

CRISPR Medicine Blog / 11.19

Turning CRISPR into a bacteria killer. A new principle in antibiotics

 
SNIPR_BIOME_Finans_Press.jpg

Finans / 11.19

Danish biotech company to develop ground-breaking replacement for penicillin
[in Danish]

 
SNIPR_BIOME_IDA_Techtopia.jpg

IDA / 08.19

Danish CRISPR startup to develop replacement for penicillin [in Danish]

 
SNIPR_Biome_Pharma.jpg

Pharma / 06.19

The biotech company SNIPR Biome wants to hit bacteria precisely [in Danish]

 
SNIPR_Lab.jpg

Press Release / 05.19

US Patent Grants Strengthen SNIPR BIOME’s Approach to Enhance Immuno-Oncology Outcomes by Microbiome Modulation

 
Bio_Century_SNIPR.jpg

BioCentury Innovations / 05.19

SNIPR: Turning CRISPR into a microbiome suicide

 
Fierce_Biotech_SNIPR.jpg

FierceBiotech / 03.19

SNIPR raises $50M to use CRISPR to modulate the microbiome

 
Bio_Century.jpg

BioCentury / 03.19

$50M series A for CRISPR microbiome play SNIPR BIOME

 
20190311_Endpoint.jpg

Endpoint News / 03.19

Lundbeck fund backs a $50M launch round for SNIPR Biome, a new brand of CRISPR Cas biotech

 
20190311_BORSEN.jpg

Børsen / 03.19

Biotech baby raises DKK 320 million to develop replacement for penicillin [in Danish]

 
SNIPR_Biome_Press.jpg

Press Release / 03.19

SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials

 
Press_01.jpg

Børsen / 08.17

Owner of Lundbeck stakes millions on bacteria killer SNIPR [in Danish]

 
Press_02.jpg

Berlingske Tidene / 08.17

Owner of Lundbeck stakes millions on bacteria killers [in Danish]

 
Press_03.jpg

Lundbeckfonden / 08.17

Owner of Lundbeck invests in CRISPR technology for bacterial gene editing
[in Danish]